mp.weixin.qq.com·· 15 hours agoPickScore83
FDA Approves GSK's Hibsago (bepirovirsen) With Nucleos(t)ide Analogues for Certain Adults With Chronic Hepatitis B
In brief
On October 20, 2026, the FDA approved GSK's Hibsago (bepirovirsen) for use with nucleos(t)ide analogues in adults with chronic hepatitis B who meet specific criteria and have no cirrhosis.
Why it matters
The material distinguishes the 24% meeting predefined stopping criteria from the 19% reaching the primary endpoint after stopping all therapy, and lists low HBsAg subgroup data, helping define the eligible boundaries of this ASO regimen.
Source: mp.weixin.qq.com · mp.weixin.qq.com